← Back to Clinical Trials
Recruiting NCT07147517

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Respiratory Infection Virus
Sponsor University of California, San Diego
Study Type OBSERVATIONAL
Phase N/A
Enrollment 25,000
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2025-10-08
Completion 2030-09-01
Interventions
Component A0Component A1Component A2

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The CHARM network will be established through three primary institutions-Beth Israel Deaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and the University of Washington (UW)-along with their subcontracting institutions. At UCSD and partner sites, the CHARM network will be implemented via the PREVENT project. All PREVENT participants will be consented in to Component A0 (Community Testing) and a subset of A0 participants will be invited to participate and will be consented into the other components: Component A (Ongoing Testing); Component A Sub-study (Immunology); Component B (Household Transmission). Component A0 participants (Community testing) will be members of the community who are interested in accessing testing for respiratory infections and will be asked to provide limited information that will then be used for screening for study Components A and/or B. Participants in Component A (Ongoing Testing ) will undergo weekly symptom screening. If they report symptoms, they will be asked to provide a nasal swab and complete illness questionnaires on the day they report symptoms (Day 0) and again on Days 7 and 14. Participants in Component A Sub-study (Immunology) will provide blood and saliva/nasal fluid samples twice a year, as well as before and after infection and/or immunization against priority pathogens. Participants in Component B (Household Transmission) will complete daily symptom questionnaires and nasal swabs for 14 days following enrollment, regardless of symptoms. Those who are symptomatic at enrollment will also complete retrospective daily diaries from symptom onset to the enrollment date. Additionally, they provide blood and/or saliva/nasal fluid samples at enrollment and again 28 days later. For all Components, UCSD will provide PCR test results for SARS-CoV-2, Influenza A/B, and RSV for nasal swab samples.

Eligibility Criteria

Community Testing Component: Inclusion: \- All community members are able to participate in the community testing component. Exclusion: \- There is no exclusion criteria and participants will not be excluded based on pregnancy status or age. For Component A: Inclusion: * All ages * AND Lives in service area of a recruitment center (i.e., within range of courier pick up) * AND Plans to remain living in a recruitment area for the next 2 years. Exclusion: * Inability to communicate in a language in which consent forms, materials, etc. are available * OR Incarcerated * OR Living in a congregate setting (e.g., assisted living, nursing home, university dormitories with shared bathroom and communal eating facilities) * OR Unable/unwilling to participate in planned data and specimen collections * OR Unable to comply with study procedures, as determined by study investigators * OR Participation in clinical trials of investigational agents for respiratory viral infections during the three months

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}